ERBB2 and aneurysmal bone cyst: In PALOMA-3 and MONARCH-2, both studies included premenopausal women with HR-positive, HER2-negative ABC who progressed on ET, receiving fulvestrant + CDK4/6 inhibitor, palbociclib in PALOMA-3 and abemaciclib in MONARCH-2, both improving mPFS.